JPH01211494A - Production of optically active alpha-hydroxyoxide - Google Patents
Production of optically active alpha-hydroxyoxideInfo
- Publication number
- JPH01211494A JPH01211494A JP3824588A JP3824588A JPH01211494A JP H01211494 A JPH01211494 A JP H01211494A JP 3824588 A JP3824588 A JP 3824588A JP 3824588 A JP3824588 A JP 3824588A JP H01211494 A JPH01211494 A JP H01211494A
- Authority
- JP
- Japan
- Prior art keywords
- formula
- lactobacillus
- alpha
- culture
- assymetric
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000004519 manufacturing process Methods 0.000 title claims description 4
- 241000186660 Lactobacillus Species 0.000 claims abstract description 11
- 229940039696 lactobacillus Drugs 0.000 claims abstract description 10
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims abstract description 7
- 125000000217 alkyl group Chemical group 0.000 claims abstract description 7
- 125000003710 aryl alkyl group Chemical group 0.000 claims abstract description 7
- 125000002252 acyl group Chemical group 0.000 claims abstract description 6
- 125000002947 alkylene group Chemical group 0.000 claims abstract description 5
- 229910052799 carbon Inorganic materials 0.000 claims abstract description 5
- 150000003839 salts Chemical class 0.000 claims abstract description 5
- 150000001875 compounds Chemical class 0.000 claims description 22
- -1 α-hydroxy acid compound Chemical class 0.000 claims description 12
- 229940061720 alpha hydroxy acid Drugs 0.000 claims description 4
- 239000001257 hydrogen Substances 0.000 claims description 4
- 229910052739 hydrogen Inorganic materials 0.000 claims description 4
- 239000000126 substance Substances 0.000 claims description 3
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims 1
- 244000199866 Lactobacillus casei Species 0.000 abstract description 8
- 235000013958 Lactobacillus casei Nutrition 0.000 abstract description 8
- 239000002994 raw material Substances 0.000 abstract description 2
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 21
- 238000011282 treatment Methods 0.000 description 18
- 238000006243 chemical reaction Methods 0.000 description 14
- 238000000034 method Methods 0.000 description 11
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 9
- 108090000790 Enzymes Proteins 0.000 description 8
- 102000004190 Enzymes Human genes 0.000 description 8
- 210000004027 cell Anatomy 0.000 description 7
- 229940017800 lactobacillus casei Drugs 0.000 description 7
- 244000005700 microbiome Species 0.000 description 7
- 238000006722 reduction reaction Methods 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 6
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 6
- 230000001580 bacterial effect Effects 0.000 description 6
- 239000000203 mixture Substances 0.000 description 6
- 235000019441 ethanol Nutrition 0.000 description 5
- 150000003053 piperidines Chemical class 0.000 description 5
- 238000000746 purification Methods 0.000 description 5
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 4
- 239000000284 extract Substances 0.000 description 4
- 239000008103 glucose Substances 0.000 description 4
- 230000000813 microbial effect Effects 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- 229910000019 calcium carbonate Inorganic materials 0.000 description 3
- 229910001873 dinitrogen Inorganic materials 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 235000013372 meat Nutrition 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 229910052757 nitrogen Inorganic materials 0.000 description 3
- 239000003921 oil Substances 0.000 description 3
- 235000019198 oils Nutrition 0.000 description 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 3
- 238000011218 seed culture Methods 0.000 description 3
- 235000017557 sodium bicarbonate Nutrition 0.000 description 3
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 3
- 239000005541 ACE inhibitor Substances 0.000 description 2
- 229920001817 Agar Polymers 0.000 description 2
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
- 229920002261 Corn starch Polymers 0.000 description 2
- 101710088194 Dehydrogenase Proteins 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 239000008272 agar Substances 0.000 description 2
- 150000001298 alcohols Chemical class 0.000 description 2
- 125000004453 alkoxycarbonyl group Chemical group 0.000 description 2
- 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 description 2
- FLSUQKXDDBANHE-UHFFFAOYSA-N benzyl 4-(6-ethoxy-5,6-dioxohexyl)piperidine-1-carboxylate Chemical compound C1CC(CCCCC(=O)C(=O)OCC)CCN1C(=O)OCC1=CC=CC=C1 FLSUQKXDDBANHE-UHFFFAOYSA-N 0.000 description 2
- 229940041514 candida albicans extract Drugs 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 235000014633 carbohydrates Nutrition 0.000 description 2
- 239000001569 carbon dioxide Substances 0.000 description 2
- 229910002092 carbon dioxide Inorganic materials 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 239000000919 ceramic Substances 0.000 description 2
- 239000002131 composite material Substances 0.000 description 2
- 239000008120 corn starch Substances 0.000 description 2
- 229940099112 cornstarch Drugs 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
- 239000003925 fat Substances 0.000 description 2
- 235000019197 fats Nutrition 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- 238000000855 fermentation Methods 0.000 description 2
- 230000004151 fermentation Effects 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 235000013312 flour Nutrition 0.000 description 2
- 239000007789 gas Substances 0.000 description 2
- 238000000227 grinding Methods 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 150000002431 hydrogen Chemical group 0.000 description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 description 2
- 239000011707 mineral Substances 0.000 description 2
- 235000010755 mineral Nutrition 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 235000005985 organic acids Nutrition 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 230000003204 osmotic effect Effects 0.000 description 2
- 230000003068 static effect Effects 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 239000012138 yeast extract Substances 0.000 description 2
- LVRFTAZAXQPQHI-YFKPBYRVSA-N (S)-2-hydroxy-4-methylpentanoic acid Chemical compound CC(C)C[C@H](O)C(O)=O LVRFTAZAXQPQHI-YFKPBYRVSA-N 0.000 description 1
- PAWQVTBBRAZDMG-UHFFFAOYSA-N 2-(3-bromo-2-fluorophenyl)acetic acid Chemical compound OC(=O)CC1=CC=CC(Br)=C1F PAWQVTBBRAZDMG-UHFFFAOYSA-N 0.000 description 1
- LBLYYCQCTBFVLH-UHFFFAOYSA-N 2-Methylbenzenesulfonic acid Chemical compound CC1=CC=CC=C1S(O)(=O)=O LBLYYCQCTBFVLH-UHFFFAOYSA-N 0.000 description 1
- NYHNVHGFPZAZGA-UHFFFAOYSA-N 2-hydroxyhexanoic acid Chemical compound CCCCC(O)C(O)=O NYHNVHGFPZAZGA-UHFFFAOYSA-N 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- 101710129690 Angiotensin-converting enzyme inhibitor Proteins 0.000 description 1
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- 101710086378 Bradykinin-potentiating and C-type natriuretic peptides Proteins 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 101710152053 D-2-hydroxyisocaproate dehydrogenase Proteins 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 101000925662 Enterobacteria phage PRD1 Endolysin Proteins 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 241000186610 Lactobacillus sp. Species 0.000 description 1
- 241000192132 Leuconostoc Species 0.000 description 1
- 241000192129 Leuconostoc lactis Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000192134 Oenococcus oeni Species 0.000 description 1
- 239000001888 Peptone Substances 0.000 description 1
- 108010080698 Peptones Proteins 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 102000007327 Protamines Human genes 0.000 description 1
- 108010007568 Protamines Proteins 0.000 description 1
- 230000010757 Reduction Activity Effects 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 239000012670 alkaline solution Substances 0.000 description 1
- 150000001280 alpha hydroxy acids Chemical class 0.000 description 1
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 235000019270 ammonium chloride Nutrition 0.000 description 1
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 1
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 1
- 235000011130 ammonium sulphate Nutrition 0.000 description 1
- 239000002518 antifoaming agent Substances 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- QLULGSLAHXLKSR-UHFFFAOYSA-N azane;phosphane Chemical compound N.P QLULGSLAHXLKSR-UHFFFAOYSA-N 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 1
- RKXUSINLWJIUOW-UHFFFAOYSA-N benzyl 4-(6-ethoxy-5-hydroxy-6-oxohexyl)piperidine-1-carboxylate Chemical compound C1CC(CCCCC(O)C(=O)OCC)CCN1C(=O)OCC1=CC=CC=C1 RKXUSINLWJIUOW-UHFFFAOYSA-N 0.000 description 1
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 238000007664 blowing Methods 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 239000000679 carrageenan Substances 0.000 description 1
- 229920001525 carrageenan Polymers 0.000 description 1
- 235000010418 carrageenan Nutrition 0.000 description 1
- 229940113118 carrageenan Drugs 0.000 description 1
- 239000003518 caustics Substances 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 235000012343 cottonseed oil Nutrition 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 description 1
- 229910000396 dipotassium phosphate Inorganic materials 0.000 description 1
- 235000019797 dipotassium phosphate Nutrition 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 238000005189 flocculation Methods 0.000 description 1
- 230000016615 flocculation Effects 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 238000002523 gelfiltration Methods 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 238000005658 halogenation reaction Methods 0.000 description 1
- 150000002367 halogens Chemical group 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 238000004255 ion exchange chromatography Methods 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 238000001155 isoelectric focusing Methods 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- 229940099596 manganese sulfate Drugs 0.000 description 1
- 239000011702 manganese sulphate Substances 0.000 description 1
- 235000007079 manganese sulphate Nutrition 0.000 description 1
- SQQMAOCOWKFBNP-UHFFFAOYSA-L manganese(II) sulfate Chemical compound [Mn+2].[O-]S([O-])(=O)=O SQQMAOCOWKFBNP-UHFFFAOYSA-L 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 150000004702 methyl esters Chemical class 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 239000003471 mutagenic agent Substances 0.000 description 1
- 231100000707 mutagenic chemical Toxicity 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 229920005615 natural polymer Polymers 0.000 description 1
- 125000001477 organic nitrogen group Chemical group 0.000 description 1
- 235000019319 peptone Nutrition 0.000 description 1
- UYWQUFXKFGHYNT-UHFFFAOYSA-N phenylmethyl ester of formic acid Natural products O=COCC1=CC=CC=C1 UYWQUFXKFGHYNT-UHFFFAOYSA-N 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 229920005597 polymer membrane Polymers 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 239000005373 porous glass Substances 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- LWIHDJKSTIGBAC-UHFFFAOYSA-K potassium phosphate Substances [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 125000001501 propionyl group Chemical group O=C([*])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 229940048914 protamine Drugs 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 238000005185 salting out Methods 0.000 description 1
- DCKVNWZUADLDEH-UHFFFAOYSA-N sec-butyl acetate Chemical compound CCC(C)OC(C)=O DCKVNWZUADLDEH-UHFFFAOYSA-N 0.000 description 1
- 238000004062 sedimentation Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 239000002689 soil Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000005063 solubilization Methods 0.000 description 1
- 230000007928 solubilization Effects 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000005694 sulfonylation reaction Methods 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 229920001059 synthetic polymer Polymers 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 150000004685 tetrahydrates Chemical class 0.000 description 1
- 238000010257 thawing Methods 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 238000009210 therapy by ultrasound Methods 0.000 description 1
- 229920002803 thermoplastic polyurethane Polymers 0.000 description 1
- YWYZEGXAUVWDED-UHFFFAOYSA-N triammonium citrate Chemical compound [NH4+].[NH4+].[NH4+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O YWYZEGXAUVWDED-UHFFFAOYSA-N 0.000 description 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 1
- 238000002525 ultrasonication Methods 0.000 description 1
- 238000009281 ultraviolet germicidal irradiation Methods 0.000 description 1
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 1
Landscapes
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
Description
【発明の詳細な説明】
産業上の利用分野
本発明は医薬品などの合成原料として有用な光学活性α
−ヒドロキシ酸化合物の製造法に関する。[Detailed Description of the Invention] Industrial Application Field The present invention is directed to the use of optically active
- A method for producing a hydroxy acid compound.
さらに詳しくは、本発明はラクトバチルス(Lacto
bacillus)属に属する菌株の培養物またはその
処理物と一般式
〔式中、R1はアラルキルまたはアシルを示し、R7は
水素、低級アルキルまたはアラルキルを示し、Xはアル
キレンを示す〕で表わされる化合物とを接触させ、一般
式(1)で表わされる化合物を不斉還元することを特徴
とする、一般式
〔式中、(*)で示される不斉炭素はR−配位またはS
−配位を示し、他の記号は前記と同意義〕で表わされる
光学活性α−ヒドロキシ酸化合物またはその塩の製造法
に関する。More specifically, the present invention relates to Lactobacillus (Lactobacillus).
A culture of a strain belonging to the genus Bacillus or a processed product thereof, and a compound represented by the general formula [wherein R1 represents aralkyl or acyl, R7 represents hydrogen, lower alkyl or aralkyl, and X represents alkylene]. The compound represented by the general formula (1) is asymmetrically reduced by contacting with
- coordination, and other symbols have the same meanings as above], or a salt thereof.
従来の技術
α−オキソ酸化合物から光学活性α−ヒドロキシ酸化合
物を、微生物または酵素を用いる不斉還元によって製造
する方法としては、パン酵母を用いる方法(ヨーロッパ
特許公開EP−A−0187037、特開昭62−14
9658号公報など)、ラクトバチルス・コンツユサス
(Lactobacillusconrusus)起源
のL−2−ヒドロキシイソカプロン酸デヒドロゲナーゼ
を用いる方法(Schutte、 11゜et at、
: Appl、 Microbiol、 Bio
technol、、 + 9゜167(1984))、
ロイコノストック・オエノス(Leuconostoc
oenos)、oイコノストック0メセンテロイデ
ス(Leuconostoc mesenteroi
des)。Background Art As a method for producing an optically active α-hydroxy acid compound from an α-oxo acid compound by asymmetric reduction using microorganisms or enzymes, there is a method using baker's yeast (European Patent Publication EP-A-0187037, JP 1986-14
9658, etc.), a method using L-2-hydroxyisocaproic acid dehydrogenase derived from Lactobacillus conrusus (Schutte, 11゜et at,
: Appl, Microbiol, Bio
technol, +9°167 (1984)),
Leuconostoc
oenos), o Iconostoc 0 mesenteroides (Leuconostoc mesenteroi)
des).
ロイコノストック・ラクチス(Leuconostoc
lactjs)、ラクトバチルス・カゼイ・サブスペシ
ーズ・シュウドプランタラム(Lactobacill
uscasei 5ubsp、 pseudopl
antarum)、ラクトバチルス・カゼイ・サブスペ
シーズ・ラムノサス(Lactobacillus
casei 5ubsp、 rhamnosus)ま
たはラクトバチルス・カゼイ・サブスペシーズ・アラク
トサス(Lactobacillus casei
5absp。Leuconostoc lactis
lactjs), Lactobacillus casei subspecies pseudoplantarum
uscasei 5ubsp, pseudopl
antarum), Lactobacillus casei subspecies rhamnosus
casei 5ubsp, rhamnosus) or Lactobacillus casei subspecies lactosus (Lactobacillus casei 5ubsp, rhamnosus)
5absp.
alactosus)に属する細菌起源のD−2−ヒド
ロキシイソカプロン酸デヒドロゲナーゼを用いる方法(
Hummel W、 et al : Appl、
Microbiol、 Bio −technol
、、21.7(1985))が知られているが、パン酵
母は収率およびエナンチオマー過剰率(e、e、)が低
い点で工業的に有利な方法とはいえず、また、D−また
はL−ヒドロキシカプロン酸デヒドロゲナーゼは、式(
1)で表わされるピペリジン誘導体あるいはさらに、そ
のカルボキシル基がエステル化されたものである該誘導
体の、α−カルボニル基に対する不斉還元の反応性の有
無に関しては、まったく知られていない。A method using D-2-hydroxyisocaproate dehydrogenase of bacterial origin belonging to P. alactosus (
Hummel W, et al: Appl.
Microbiol, Bio-technol
D- Or L-hydroxycaproate dehydrogenase is expressed by the formula (
It is not known at all whether the piperidine derivative represented by 1) or the derivative obtained by esterifying its carboxyl group has reactivity in asymmetric reduction with respect to an α-carbonyl group.
発明が解決しようとする課題
本発明は、高血圧症、心臓病、脳卒中などの循環器系疾
患の治療剤であるアンジオテンシン変換酵素阻害剤の合
成原料として有用な、式(II)で示されるピペリジン
誘導体の光学活性なα−(R)−ヒドロキシ酸またはα
−(S)−ヒドロキシ酸を製造するために、式(1)で
示される、相当するα−カルボニル基を有するピペリジ
ン誘導体を不斉還元して、当該式(II)で示されるα
−ヒドロキシ酸化合物を効率よく製造する方法を提供す
るものである。Problems to be Solved by the Invention The present invention provides a piperidine derivative represented by formula (II) that is useful as a raw material for the synthesis of angiotensin-converting enzyme inhibitors, which are therapeutic agents for cardiovascular diseases such as hypertension, heart disease, and stroke. optically active α-(R)-hydroxy acid or α
In order to produce -(S)-hydroxy acid, a piperidine derivative having a corresponding α-carbonyl group represented by formula (1) is asymmetrically reduced, and α represented by formula (II) is
- Provides a method for efficiently producing hydroxy acid compounds.
課題を解決するための手段
本発明者らは、ピペリジン誘導体のα−カルボニル基を
還元して、相当する光学活性なα−ヒドロキシ酸を効率
よく生成しうる微生物を、鋭意探索してその取得に成功
し、さらに研究を重ねた結果、本発明を完成するに至っ
た。Means for Solving the Problems The present inventors have actively searched for microorganisms that can efficiently produce the corresponding optically active α-hydroxy acid by reducing the α-carbonyl group of piperidine derivatives, and have set out to obtain the same. As a result of this success and further research, we have completed the present invention.
本発明の不斉還元反応に用いられる微生物菌株としては
ラクトバチルス属細菌、特にラクトバチルス・カゼイ・
サブスペシーズ・カゼイ(Lacto−bacillu
s casei 5ubsp、 casei)また
はラクトバチルス−エスピー(Lactobacill
us sp、)が好んで用いられるが、菌株は特に限
定されるものではなく、新たに土壌、食品、動植物など
から分離した株であっても、式(1)で表わされる化合
物を不斉還元して式(II)で表わされる化合物を産生
ずる能力を有するものであれば、本発明の方法に使用で
きる。またそれらの菌株に紫外線照射や変異剤処理を施
して、人為的に変異を誘起させた株や、当該還元活性の
発現に必要な遺伝子断片を人為的にとりだし、それを組
みいれた他の微生物菌体であっても、本発明の方法に使
用できる。The microbial strain used in the asymmetric reduction reaction of the present invention includes Lactobacillus bacteria, particularly Lactobacillus casei.
Subspecies casei (Lacto-bacillus)
s casei 5ubsp, casei) or Lactobacillus sp.
US sp, ) is preferably used, but the strain is not particularly limited, and even strains newly isolated from soil, food, animals and plants can be used to asymmetrically reduce the compound represented by formula (1). Any compound capable of producing the compound represented by formula (II) can be used in the method of the present invention. In addition, there are strains that have been artificially mutated by UV irradiation or treatment with mutagens, and other microorganisms that have been artificially extracted and incorporated with gene fragments necessary for expressing the reduction activity. Even bacterial cells can be used in the method of the present invention.
式(1)で表わされるピペリジン誘導体のα−カルボニ
ル基を不斉還元するのに用いられる菌株の具体例として
は、Lactobacillus casei 5
ubsp。A specific example of a strain used for asymmetric reduction of the α-carbonyl group of the piperidine derivative represented by formula (1) is Lactobacillus casei 5.
ubsp.
casei I F 0 12004株またはLac
tobac i −11us sp、 I P 0
3954株があげられる。本菌株は財団法人発酵研究
所発行の[リスト・オブ・カルチャーズ(List
or Cu1tures)、第7版、1984J61
頁、62頁にそれぞれ掲載されている公知菌株であり、
財団法人発酵研究所より容易に入手できる。これらのう
ち光学活性なα−(R)−ヒドロキシ酸化合物を得るた
めには前者が好んで用いられ、α−(S)−ヒドロキシ
酸化合物を得るためには後者が好んで用いられる。casei I F 0 12004 strain or Lac
tobac i-11us sp, IP 0
There are 3,954 stocks. This strain is included in the [List of Cultures] published by the Fermentation Research Institute.
or Cultures), 7th edition, 1984J61
These are known strains listed on pages 62 and 62, respectively.
It is easily available from the Fermentation Research Institute. Among these, the former is preferably used to obtain an optically active α-(R)-hydroxy acid compound, and the latter is preferably used to obtain an α-(S)-hydroxy acid compound.
これらの微生物菌株を培養するには、通常の静置培養、
振盪培養、通気攪拌培養あるいは固体培養などにより連
続的あるいは間欠的に行なうことができる。用いる培地
は、使用する微生物の生育しうる通常の組成のものでよ
く、炭素源には炭水化物、油脂、脂肪酸、有機酸あるい
はアルコール類などのなかから資化しうるちのを適宜選
択し、単独または混合して使用される。また窒素源には
例えばペプトン、大豆粉、綿実粉、コーンステイープリ
カー、酵母エキス、肉エキス、麦芽エキス、尿素などの
有機窒素源のほか、硫安、塩安、硝安、燐安などの無機
窒素源が必要に応じて、適宜混合してまたは単独で用い
られる。培地には炭素源、窒素源のほか生育に必要なミ
ネラル、アミノ酸あるいはビタミンなどの生育必須因子
や生育促進物質を添加するのがよい。To cultivate these microbial strains, conventional static culture,
This can be carried out continuously or intermittently by shaking culture, aerated agitation culture, solid state culture, or the like. The medium used may have a normal composition that allows the microorganisms used to grow, and the carbon source may be selected from among carbohydrates, fats and oils, fatty acids, organic acids, alcohols, etc., and may be used singly or in combination. used as Nitrogen sources include organic nitrogen sources such as peptone, soybean flour, cottonseed flour, cornstarch liquor, yeast extract, meat extract, malt extract, and urea, as well as inorganic sources such as ammonium sulfate, ammonium chloride, ammonium nitrate, and ammonium phosphorus. Nitrogen sources may be used alone or in combination as appropriate. In addition to a carbon source and a nitrogen source, essential growth factors and growth-promoting substances such as minerals, amino acids, and vitamins necessary for growth are preferably added to the medium.
培養中のp)(および泡の管理の目的で苛性アルカリ液
、炭酸ナトリウム液、カルシウム塩類を適宜添加するこ
とができ、また、消泡剤の添加も有効である。さらに、
環境を嫌気状態にする目的で窒素ガスや炭酸ガスを通気
するのも有効である。p) during culture (and for the purpose of foam management, caustic alkaline solution, sodium carbonate solution, calcium salts can be added as appropriate, and addition of an antifoaming agent is also effective.Furthermore,
It is also effective to aerate nitrogen gas or carbon dioxide gas to make the environment anaerobic.
培養の温度は、用いる微生物の成育に適した温度を選択
すればよく、通常15℃乃至55℃、好ましくは25℃
乃至45℃で培養するのが有利である。また培養の時間
は、用いる微生物の生育に十分な時間続行されるが、通
常5乃至48時間である。The culture temperature may be selected to be suitable for the growth of the microorganism used, and is usually 15°C to 55°C, preferably 25°C.
It is advantageous to culture at between 45°C and 45°C. The culture is continued for a sufficient period of time for the growth of the microorganism used, and is usually 5 to 48 hours.
このようにして培養後、該菌株は、培養された培養物の
まま、もしくは何らかの分離手段、例えば遠心分離、沈
降分離、凝集分離、多孔性膜や高分子膜、セラミック膜
などによるろ過などの方法によって分離された微生物菌
体のまま、あるいはその処理物が不斉還元反応に供され
る。本発明で用いられる「処理物」とは、上記で得られ
る培養物を物理化学的処理たとえばろ過、遠心分離、超
音波処理、フレンチプレス処理、浸透圧処理、凍結融解
処理、アルミナ磨砕処理、溶菌酵素処理、界面活性剤処
理または有機溶媒処理などで得た菌体あるいは、化合物
(I)のα−カルボニル基を不斉還元する活性を有する
酵素を含む菌体破砕物をいう。また、後記の方法で精製
して得られる該酵素あるいは固定化した菌体もしくは該
酵素も用いることができる。該酵素は、上記で得られる
菌体を、例えば凍結融解処理、磨砕処理、超音波処理、
浸透圧処理、細胞壁膜の溶解処理、界面活性剤処理など
の物理化学的処理に付すことにより可溶化することがで
きる。また、可溶化された酵素はさらにプロタミン処理
、塩析、有機溶媒処理、等電点沈殿、電気泳動、イオン
交換クロマトグラフィー、ゲルろ過、アフィニティーク
ロマトグラフィー、晶出などの通常の酵素の精製手段を
適宜組み合わせることによって精製することができる。After culturing in this manner, the strain may be used as a cultivated culture, or by some separation method such as centrifugation, sedimentation, flocculation, filtration using a porous membrane, polymer membrane, ceramic membrane, etc. The microbial cells isolated by the method or the processed product thereof are subjected to an asymmetric reduction reaction. The "processed product" used in the present invention refers to the culture obtained as described above subjected to physicochemical treatments such as filtration, centrifugation, ultrasonic treatment, French press treatment, osmotic pressure treatment, freeze-thaw treatment, alumina grinding treatment, etc. It refers to bacterial cells obtained by lytic enzyme treatment, surfactant treatment, organic solvent treatment, etc., or crushed bacterial cells containing an enzyme having the activity of asymmetrically reducing the α-carbonyl group of compound (I). Furthermore, the enzyme obtained by purification by the method described later, or immobilized bacterial cells or the enzyme can also be used. The enzyme can be used by subjecting the bacterial cells obtained above to, for example, freeze-thawing treatment, grinding treatment, ultrasonication treatment,
Solubilization can be achieved by subjecting to physicochemical treatments such as osmotic pressure treatment, cell wall membrane dissolution treatment, and surfactant treatment. In addition, the solubilized enzyme is further subjected to conventional enzyme purification methods such as protamine treatment, salting out, organic solvent treatment, isoelectric focusing precipitation, electrophoresis, ion exchange chromatography, gel filtration, affinity chromatography, and crystallization. Purification can be achieved by appropriately combining them.
得られる酵素は寒天やカラギーナンなどの天然高分子、
ポリアクリルアミドやウレタン樹脂などの合成高分子に
包括固定あるいは、活性炭、セラミック、デキストラン
、アガロース系物質、多孔性ガラスなどの担体に結合固
定することができる。The enzymes obtained are natural polymers such as agar and carrageenan,
It can be encircled and immobilized on a synthetic polymer such as polyacrylamide or urethane resin, or it can be bonded and immobilized on a carrier such as activated carbon, ceramic, dextran, agarose-based material, or porous glass.
式(1)中R3で示される低級アルキル基としては、例
えばメチル、エチル、プロピル、イソプロピル、ブチル
、イソブチル、5ec−ブチル、tert−ブチルなど
の炭素数1乃至4程度のアルキル基があげられ、また、
R3またはR,で示されるアラルキル基としては例えば
ベンジル、フェネチル、3−フェニルプロピル、α−メ
チルベンジル、α−エチルベンジル、α−メチルフェネ
チル、β−メチルフェネチル、β−エチルフェネチルな
どのフェニル低級(01〜4)アルキル基があげられる
。R1で示されるアシル基としては例えば低級(C,〜
、)アルカノイル(例、アセチル、プロピオニル)、ベ
ンゾイル。Examples of the lower alkyl group represented by R3 in formula (1) include alkyl groups having about 1 to 4 carbon atoms, such as methyl, ethyl, propyl, isopropyl, butyl, isobutyl, 5ec-butyl, and tert-butyl. Also,
Examples of the aralkyl group represented by R3 or R include phenyl lower ( 01-4) Alkyl groups. Examples of the acyl group represented by R1 include lower (C, ~
,) alkanoyl (e.g. acetyl, propionyl), benzoyl.
フェニル低級(C3〜4)アルコキシカルボニル(例、
ベンジルオキシカルボニル)、低級(C+〜4)アルコ
キシカルボニル(例、tert−ブトキシカルボニル)
などのアシル基があげられる。Xで示されるアルキレン
鎖としては例えば直鎖状もしくは分枝状の炭素数1乃至
7程度のアルキレン鎖があげられ、例えばメチレン、エ
チレン、トリメチレン、テトラメチレン、ペンタメチレ
ン、ヘキサメチレン、ヘプタメチレン、プロピレン、エ
チルメチレン、ジメチルテトラメチレンなどの2価基が
あげられる。該アルキレン鎖は鎖内に不飽和結合(例、
2重結合、3重結合)を有していてもよい。これらの化
合物のうちでも、6−(1−アシル−4−ピペリジル)
−2−オキソヘキサン酸またはその低級(C4〜4)ア
ルコールエステルが好ましく、とりわけ6−(1−ベン
ジルオキシカルボニル−4−ピペリジル)−2−オキソ
ヘキサン酸の低級(CI、、)アルコールエステルが好
ましい。化合物(1)とラクトバチルス属に属する菌株
の培養物もしくはその処理物とを接触させて行う反応に
おける反応液中の化合物(1)の濃度は好ましくは0.
1%乃至20%、より好ましくは0.5%乃至5%がよ
い。さらには、式(1)で表わされる化合物とともに水
素供与を目的として、該微生物が資化しうる炭素源(例
、炭水化物、油脂、脂肪酸、有機酸、アルコール類)を
添加するのが好ましく、また反応を促進するためにミネ
ラル類やビタミン類を添加してもさしつかえない。Phenyl lower (C3-4) alkoxycarbonyl (e.g.
benzyloxycarbonyl), lower (C+~4) alkoxycarbonyl (e.g. tert-butoxycarbonyl)
Examples include acyl groups such as Examples of the alkylene chain represented by , ethylmethylene, dimethyltetramethylene, and other divalent groups. The alkylene chain has an unsaturated bond within the chain (e.g.
double bond, triple bond). Among these compounds, 6-(1-acyl-4-piperidyl)
-2-oxohexanoic acid or its lower (C4-4) alcohol ester is preferred, and lower (CI,) alcohol ester of 6-(1-benzyloxycarbonyl-4-piperidyl)-2-oxohexanoic acid is particularly preferred. . The concentration of compound (1) in the reaction solution in the reaction carried out by bringing compound (1) into contact with a culture of a strain belonging to the genus Lactobacillus or a treated product thereof is preferably 0.
It is preferably 1% to 20%, more preferably 0.5% to 5%. Furthermore, it is preferable to add a carbon source that can be assimilated by the microorganisms (e.g., carbohydrates, fats and oils, fatty acids, organic acids, alcohols) together with the compound represented by formula (1) for the purpose of hydrogen donation. Minerals and vitamins may be added to promote this.
反応の温度は不斉還元反応が進行しうる範囲のものであ
ればよいが、通常好ましくは20乃至60℃の範囲、よ
り好ましくは25乃至45℃の範囲が選ばれる。pHの
範囲は、好ましくはpH2乃至lOであるが、より好ま
しくはpH5乃至7である。反応中機生物菌体またはそ
の処理物と式(1)で表わされる化合物との接触をよく
するために、反応液を適宜攪拌するのが望ましいが、還
元反応をより効率よく進行させるために、雰囲気を嫌気
状態に維持するのが好ましく、そのために窒素ガスまた
は炭酸ガスを通気するのもよい。The reaction temperature may be within a range that allows the asymmetric reduction reaction to proceed, but it is usually preferably in the range of 20 to 60°C, more preferably in the range of 25 to 45°C. The pH range is preferably pH 2 to 1O, more preferably pH 5 to 7. During the reaction, it is desirable to stir the reaction solution appropriately in order to improve the contact between the microbial cells or their processed product and the compound represented by formula (1). Preferably, the atmosphere is maintained in an anaerobic state, for which purpose nitrogen gas or carbon dioxide gas may also be passed through.
反応は、式(I)で表わされるα−オキソ酸化合物が不
斉還元されるまでの時間続行されるが、通常2乃至10
0時間である。The reaction is continued for a period of time until the α-oxo acid compound represented by formula (I) is asymmetrically reduced, but is usually 2 to 10 hours.
It is 0 hours.
このようにして反応後、生成した光学活性なα−ヒドロ
キシ酸化合物は通常の公知の抽出、濃縮等の精製方法を
組み合わせることによって、容易に回収、採取すること
ができる。After the reaction, the optically active α-hydroxy acid compound produced can be easily recovered and collected by combining conventional purification methods such as extraction and concentration.
R8が水素のとき、式(n)で表わされる化合物はアル
カリ金属(例、ナトリウム、カリウム)との塩を形成し
ていてもよく、式(n)で表わされる化合物の塩は上記
の反応および精製手段自体で得られることもあるが、必
要に応じて、塩基を式(II)で表わされる化合物に添
加して得ることもできる。When R8 is hydrogen, the compound represented by formula (n) may form a salt with an alkali metal (e.g., sodium, potassium), and the salt of the compound represented by formula (n) can be formed by the above reaction and Although it may be obtained by the purification method itself, it can also be obtained by adding a base to the compound represented by formula (II), if necessary.
作用
本発明により得られる化合物(n)は自体公知のハロゲ
ン化反応またはスルホニル化反応に付すことによって一
般式
〔式中、Wはハロゲン(例、塩素)または式R−sot
−o−
(式中、Rは低級(CI、4)アルキル、トリフルオロ
メチル、フェニルまたはp−)リルを示す)で表わされ
る基を示し、他の記号は前記と同意義〕で表わされる化
合物に容易に導くことができる(ヨーロッパ特許公開E
P−A−0156455,特開昭60−211668号
公報など)。さらに、化合物(I[l)を用いてアンジ
オテンシン変換酵素阻害剤(ヨーロッパ特許公開EP−
A−0156455、特開昭60−231668号公報
、ヨーロッパ特許公開EP−A−0187037,特開
昭62−149658号公報など)を容易に合成するこ
とができる。Effect Compound (n) obtained by the present invention is subjected to a halogenation reaction or a sulfonylation reaction known per se to obtain a compound of the general formula [wherein W is halogen (e.g. chlorine) or a formula R-sot
A compound represented by -o- (wherein R represents lower (CI, 4) alkyl, trifluoromethyl, phenyl or p-)lyl, and other symbols have the same meanings as above) (European Patent Publication E)
P-A-0156455, JP-A-60-211668, etc.). Furthermore, using compound (I[l), angiotensin-converting enzyme inhibitor (European patent publication EP-
A-0156455, JP-A-60-231668, European Patent Publication EP-A-0187037, JP-A-62-149658, etc.) can be easily synthesized.
実施例
以下に実施例をもって、本発明の内容をより具体的に説
明するが、これらはいずれも本発明の内容を例示するも
のにすぎず、本発明の範囲を限定するものではない。EXAMPLES The content of the present invention will be explained in more detail with reference to Examples below, but these are merely illustrative of the content of the present invention and do not limit the scope of the present invention.
実施例1
市販CAM寒天培地(日永製薬)中で穿刺培養して生育
したLactobacillus casei 5
ubsp、 caseiIFo 12004株をグル
コース2%、エールリッヒ肉エキス1%、ポリペプトン
1%、酵母エキス0.5%、燐酸2カリウム0.2%、
ツイーン80 0.1%、酢酸ソーダ0.5%、クエン
酸3アンモン0.2%、硫酸マグネシウム(7水塩)0
゜02%、硫酸マンガン(約4水塩)0.05%からな
る滅菌シード培地20m1!を含む200M1容三角フ
ラスコ15本に接種して、37℃で24時間、静置培養
した。このシード培養物3dを同じ組成からなる滅菌培
地60威を含む200d容ひだ付き三角フラスコ83本
に移植し、37℃で静置培養した。培養開始後22時間
目にエチル6−(1−ベンジルオキシカルボニル−4−
ピペリジル)−2−オキソヘキサノアート(純度68.
2%)1%、グルコース3%、炭酸カルシウム2%をそ
れぞれのフラスコに添加し、190rpmで回転振盪し
ながら96時間目まで反応させた。この反応終了液を、
412.3Q、2Qの酢酸エチルで順次抽出し、水洗後
脱水、濃縮して油状の組物質(A)50゜1gを得た。Example 1 Lactobacillus casei 5 grown by puncture culture in commercially available CAM agar medium (Hinaga Pharmaceutical)
ubsp, caseiIFo 12004 strain with 2% glucose, 1% Ehrlich meat extract, 1% polypeptone, 0.5% yeast extract, 0.2% dipotassium phosphate,
Tween 80 0.1%, sodium acetate 0.5%, triammonium citric acid 0.2%, magnesium sulfate (7 hydrate) 0
20ml of sterile seed medium consisting of 0.02% manganese sulfate (approximately tetrahydrate) and 0.05%! The mixture was inoculated into 15 200M Erlenmeyer flasks containing the following, and cultured statically at 37°C for 24 hours. 3 d of this seed culture was transplanted into 83 200 d-volume pleated Erlenmeyer flasks containing 60 volumes of a sterile medium having the same composition, and cultured stationary at 37°C. Ethyl 6-(1-benzyloxycarbonyl-4-
piperidyl)-2-oxohexanoate (purity 68.
2%) 1%, glucose 3%, and calcium carbonate 2% were added to each flask, and the reaction was allowed to proceed until 96 hours with rotational shaking at 190 rpm. This reaction completed liquid is
The extract was sequentially extracted with 412.3Q and 2Q ethyl acetate, washed with water, dehydrated and concentrated to obtain 50.1 g of oily compound (A).
これを酢酸エチルに溶かし希重曹水で洗浄して、酢酸エ
チル層から組物質(B)23゜5gを得た。また希重曹
水層を塩酸酸性にして酢酸エチルで抽出して得た油をエ
タノール!00−に溶解し、トルエン100dおよびp
−トルエンスルホン酸3.0gを加えて8時間還流した
。反応液を減圧で濃縮し、残渣を酢酸エチル120−に
溶解し、水、希重曹水および水で洗浄して酢酸エチルを
減圧で濃縮して組物質(C)23.3gを得た。This was dissolved in ethyl acetate and washed with diluted sodium bicarbonate solution to obtain 23.5 g of composite material (B) from the ethyl acetate layer. Also, the diluted sodium bicarbonate aqueous layer is acidified with hydrochloric acid and extracted with ethyl acetate, and the oil obtained is ethanol! 00-, dissolved in toluene 100d and p
- 3.0 g of toluenesulfonic acid was added and refluxed for 8 hours. The reaction solution was concentrated under reduced pressure, and the residue was dissolved in 120% of ethyl acetate, washed with water, diluted sodium bicarbonate solution and water, and the ethyl acetate was concentrated under reduced pressure to obtain 23.3 g of composite material (C).
高速液体クロマトグラフィーで組物質(B)、(C)の
エチル6−(1−ベンジルオキシカルボニル−4−ピペ
リジル)−2−ヒドロキシヘキサノアートの含量を測定
したところ、それぞれ44.2%および81.0%であ
り、収率は82,9%であった。またこれらを(−)−
α−メトキシ−α−トリフロロメチルフェニル酢酸エス
テルに導き、高速液体クロマトグラフィーで定量すると
、エナンチオマー過剰率(%e、 e、)は、それぞれ
94.4%、49.6%であり、(R)一体の収率は6
9.0%であった。When the content of ethyl 6-(1-benzyloxycarbonyl-4-piperidyl)-2-hydroxyhexanoate in compounds (B) and (C) was measured by high-performance liquid chromatography, they were 44.2% and 81%, respectively. The yield was 82.9%. Also these (-)-
When α-methoxy-α-trifluoromethylphenylacetic acid ester was derived and quantified by high performance liquid chromatography, the enantiomeric excess (%e, e,) was 94.4% and 49.6%, respectively, and (R ) The total yield is 6
It was 9.0%.
実施例2
実施例Iと同様に生育させたLactobacillu
scasei 5ubsp、 casei I F
0 12004株のシード培養物ldずつを、同じ組
成からなる滅菌培地20dを含む20〇−容ひだ付き三
角フラスコ3本に移植し、37℃で静置培養して16時
間目に、表に示す6−(1−ベンジルオキシカルボニル
−4−ピペリジル)−2−オキソヘキサン酸アルキルエ
ステル1%、グルコース3%、炭酸カルシウム2%を添
加して、二二一ブランズウィック・サイエンティフィッ
ク社製シェーカー、モデルG−24のボックス内に窒素
ガスをlQ1分で通気しながら、300 rpIllで
回転振盪して48時間目まで反応させ、実施例1と同様
に還元生成物の収率および(R)一体のエナンチオマー
過剰率(e。Example 2 Lactobacillus grown in the same manner as in Example I
casei 5ubsp, casei IF
12,004 strain seed cultures were transplanted into three 200-capacity pleated Erlenmeyer flasks containing 20 d of sterile medium with the same composition, and after 16 hours of static culture at 37°C, 6-(1-benzyloxycarbonyl-4-piperidyl)-2-oxohexanoic acid alkyl ester 1%, glucose 3%, and calcium carbonate 2% were added to shaker, model 221 Brunswick Scientific. While blowing nitrogen gas into the G-24 box at a rate of 1Q1 minute, the reaction was carried out by rotary shaking at 300 rpm for up to 48 hours, and the yield of the reduction product and the (R) integral enantiomer were determined in the same manner as in Example 1. Excess rate (e.
e、)から(R)一体の収率を調べたところ、表のよう
な結果が得られた。When the yield of (R) was investigated from (e,), the results shown in the table were obtained.
表
α−オキソニス α−ヒドロキシエ (R)一
体メチルエステル 83.2 68
.1プロピルエステル 81.671.9ブチ
ルエステル 82.3 71.5実
施例3
実施例1と同様に生育させたLactobacillu
ssp、 I P 0 3954株のシード培養物2
Fnlを、エールリッヒ肉エキスのかわりにコーンステ
イープリカーを用いたほかは、シード培地とおなじ組成
の滅菌培地40蔵を含むひだ付き三角フラスコに移植し
て、37℃で静置培養した。培養開始後22時間目にエ
チル6−(1−ベンジルオキシカルボニル−4−ピペリ
ジル)−2−オキソヘキサノアート(純度68.2%)
2%、グルコース5%、炭酸カルシウム3%を添加し、
190 rpmで回転振盪しながら66時間目まで反応
させた。反応液を等量の酢酸エチルで二回抽出し、水洗
後脱水、濃縮して油状の組物質770mgを得て、高速
液体クロマトグラフィーでエチル6−(l−ベンジルオ
キシカルボニル−4−ピペリジル)−2−ヒドロキシヘ
キサノアートの含量を測定したところ、56.8%であ
り、収率は80.2%であった。なおこのものは(R)
一体18.2%、(S)一体St。Table α-oxonis α-hydroxye (R) monolithic methyl ester 83.2 68
.. 1 Propyl ester 81.671.9 Butyl ester 82.3 71.5 Example 3 Lactobacillus grown in the same manner as in Example 1
Seed culture 2 of ssp, I P 0 3954 strain
Fnl was transplanted into a pleated Erlenmeyer flask containing 40 volumes of sterile medium with the same composition as the seed medium, except that cornstarch liquor was used instead of Ehrlich meat extract, and cultured statically at 37°C. Ethyl 6-(1-benzyloxycarbonyl-4-piperidyl)-2-oxohexanoate (purity 68.2%) 22 hours after the start of culture
2%, glucose 5%, calcium carbonate 3%,
The reaction was continued for 66 hours with rotational shaking at 190 rpm. The reaction solution was extracted twice with an equal amount of ethyl acetate, washed with water, dehydrated, and concentrated to obtain 770 mg of an oily compound.Ethyl 6-(l-benzyloxycarbonyl-4-piperidyl)- The content of 2-hydroxyhexanoate was measured to be 56.8%, and the yield was 80.2%. This one is (R)
Integrated 18.2%, (S) Integrated St.
8%の組成比であった。The composition ratio was 8%.
発明の効果Effect of the invention
Claims (1)
物と一般式 ▲数式、化学式、表等があります▼( I ) 〔式中、R_1はアラルキルまたはアシルを示し、R_
2は水素、低級アルキルまたはアラルキルを示し、Xは
アルキレンを示す〕で表わされる化合物とを接触させ、
一般式( I )で表わされる化合物を不斉還元すること
を特徴とする、一般式 ▲数式、化学式、表等があります▼(II) 〔式中、(*)で示される不斉炭素はR−配位またはS
−配位を示し、他の記号は前記と同意義〕で表わされる
光学活性α−ヒドロキシ酸化合物またはその塩の製造法
。[Claims] A culture of a strain belonging to the genus Lactobacillus or a processed product thereof and a general formula ▲ Numerical formula, chemical formula, table, etc. ▼ (I) [In the formula, R_1 represents aralkyl or acyl, R_
2 represents hydrogen, lower alkyl or aralkyl, and X represents alkylene],
There are general formulas, mathematical formulas, chemical formulas, tables, etc., which are characterized by asymmetric reduction of the compound represented by general formula (I) (II) [In the formula, the asymmetric carbon indicated by (*) is R -coordination or S
- coordination, and other symbols have the same meanings as above] A method for producing an optically active α-hydroxy acid compound or a salt thereof.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP3824588A JPH01211494A (en) | 1988-02-19 | 1988-02-19 | Production of optically active alpha-hydroxyoxide |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP3824588A JPH01211494A (en) | 1988-02-19 | 1988-02-19 | Production of optically active alpha-hydroxyoxide |
Publications (1)
Publication Number | Publication Date |
---|---|
JPH01211494A true JPH01211494A (en) | 1989-08-24 |
Family
ID=12519923
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP3824588A Pending JPH01211494A (en) | 1988-02-19 | 1988-02-19 | Production of optically active alpha-hydroxyoxide |
Country Status (1)
Country | Link |
---|---|
JP (1) | JPH01211494A (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001005996A1 (en) * | 1999-07-21 | 2001-01-25 | Kaneka Corporation | Process for producing optically active pyridineethanol derivatives |
-
1988
- 1988-02-19 JP JP3824588A patent/JPH01211494A/en active Pending
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001005996A1 (en) * | 1999-07-21 | 2001-01-25 | Kaneka Corporation | Process for producing optically active pyridineethanol derivatives |
US7329518B2 (en) | 1999-07-21 | 2008-02-12 | Kaneka Corporation | Enzyme for producing optically active pyridineethanol derivatives |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP3951008B2 (en) | Capsaicin decomposing / synthesizing enzyme and production method thereof | |
JPH01211494A (en) | Production of optically active alpha-hydroxyoxide | |
JPS58201985A (en) | Production of glucose dehydrogenase | |
JPS61265097A (en) | Production of menaquinone-4 by fermentation process | |
JPH0783706B2 (en) | How to improve the quality of alcoholic beverages | |
JP2507406B2 (en) | Method for producing D-(-)-tartaric acid | |
JP2964163B2 (en) | Method for producing R (-)-1,3-butanediol | |
JPH04152895A (en) | Production of optically active 1,3-butanediol | |
JPH0965871A (en) | Culture of maritime fine algae | |
JPH04252189A (en) | Production of benzenedicarboxlic monoester or derivative thereof | |
JP2828720B2 (en) | Method for producing optically active 1,3-butanediol | |
JPH01191697A (en) | Production of optically active carboxylic acid and its antipode ester | |
JPH08275776A (en) | New chitinase and its production | |
JPS6316119B2 (en) | ||
JPS6012993A (en) | Production of optically active carboxylic acid | |
JPH0494689A (en) | Production of optically active (s)-(+)-3-halo-1,2-propanediol | |
JPH05192187A (en) | Production of optically active 2-hydroxycycloalkanecarboxylic acid ester | |
JPH01222798A (en) | Production of optically active carboxylic acid and antipode ester thereof | |
JPS5945894A (en) | Preparation of coenzyme q10 | |
JPH0787988A (en) | Culture of marine fine algae | |
JPS6219093A (en) | Production of l-phenylalanine | |
JP2001149088A (en) | Production of optically active 1-substituted-3-amino-4- phenyl-2-butanol derivative | |
JPH07188A (en) | New microorganism and production of d-malic acid using the microorganism | |
JPS63269998A (en) | Production of optically active carboxylic acid and antipode ester thereof | |
JPH08214872A (en) | Production of optically active diol |